Navigation Links
Minneapolis Heart Institute selected to participate in Cardiovascular Cell Therapy Research Network

MINNEAPOLIS, April 2, 2012 The Cardiovascular Cell Therapy Research Network (CCTRN), a nationwide U.S. network funded by the National Institutes of Health's (NIH) National Heart, Lung and Blood Institute (NHLBI) has selected the Minneapolis Heart Institute (MHI) as one of its seven U.S. centers of excellence. The network will receive $63 million from the NIH and NHLBI over the next seven years to help achieve its mission of driving public health advances in cardiovascular cell therapy for the treatment of cardiovascular diseases.

MHI was integral to the success of the first CCTRN initiativea series of clinical studies that took place over five years involving five sites using bone marrow stem cells in patients with heart disease, and in which nearly 50 percent of the patients were enrolled in Minnesota. As principal investigator, Timothy D. Henry, MD, director of research at the MHI, will be responsible for a network of Minnesota hospitals including the Minneapolis Heart Institute at Abbott Northwestern Hospital in Minneapolis, the University of Minnesota in Minneapolis, Mayo Clinic in Rochester, United Hospital in St. Paul, Mercy Hospital in Coon Rapids and Hennepin County Medical Center in Minneapolis.

This extension of CCTRN already has three trials planned, including

  • An allogeneic mesenchymal cell for patients with advanced heart function requiring left ventricular assist device;
  • An enhanced autologous bone marrow cell for patients with claudication (leg pain while walking); and
  • A combination of a bone marrow cell and a novel cardiac derived cell for patients with heart failure.

"These trials will play a key role in identifying the benefits of cell therapy in patients with cardiovascular disease. The Minneapolis Heart Institute at Abbott Northwestern Hospital has been a leader in cardiovascular cell therapy research with more than 300 patients treated for a variety of conditions including acute heart attack, heart failure, ischemic heart disease and peripheral arterial disease," Henry said. "The first CCTRN was highly successful in achieving the NIH's goal of promoting clinical research and has led to the expansion of the network to seven clinical centers for seven years.

Henry noted the remarkable progress in cell therapy over the past several years. Currently, there are several large Phase 3 trials, which if proven efficacious, will lead to cell therapy added to the armamentarium for treating patients with challenging cardiovascular diseases. The CCTRN in particular is critical to provide key insights into the preferred cell, and method of delivery to increase the chance of success.

The CCTRN was created to support the collaboration of physicians, researchers and support staff with expertise in innovative stem cell therapies and experience in leading clinical trials that evaluate leading edge treatments for heart disease.

"Stem cell therapy holds great promise for treating heart disease, and researchers involved in CCTRN are helping determine how these promising therapies might be most beneficial to patients," said Sonia I. Skarlatos, PhD, NHBLI's deputy director of the division of cardiovascular sciences and program director of CCTRN. "This new round of funding is an important step in helping to improve cardiovascular health."

The CCTRN also includes the University of Miami, the University of Florida, Stanford University, Texas Heart Institute, Indiana University and University of Louisville.

Cardiovascular disease remains the leading cause of death in the United States, claiming nearly 900,000 lives each year and more lives than the next five leading causes of death combined. One in three Americans suffer from some form of cardiovascular disease and associated costs are estimated at $432 billion in 2007.


Contact: Kristin Wincek
Minneapolis Heart Institute Foundation

Related biology news :

1. Insects scientists to meet in Minneapolis
2. New analysis of premature infants heartbeats, breathing could be cues for leaving NICU
3. Cell therapy using patients own bone marrow may present option for heart disease
4. Geological Society of America Cordilleran section meets in the heart of Mexico
5. Heart-powered pacemaker could one day eliminate battery-replacement surgery
6. A change of heart
7. First study to show that bisphenol A exposure increases risk of future onset of heart disease
8. Pancreatic hormone linked with severe heart disease in obese and diabetic patients
9. New ability to regrow blood vessels holds promise for treatment of heart disease
10. Stem cell study in mice offers hope for treating heart attack patients
11. Freeze-dried heart valve scaffolds hold promise for heart valve replacement
Post Your Comments:
(Date:10/29/2015)... Oct. 29, 2015  Rubicon Genomics, Inc., today ... distribution of its DNA library preparation products, including ... new ThruPLEX Plasma-seq kit. ThruPLEX Plasma-seq has been ... of NGS libraries for liquid biopsies--the analysis of ... prognostic applications in cancer and other conditions. Eurofins ...
(Date:10/27/2015)... 27, 2015 Munich, Germany ... Mapping technology (ASGM) automatically maps data from mobile eye ... , so that they can be quantitatively analyzed ... Munich, Germany , October 28-29, 2015. SMI,s ... from mobile eye tracking videos created with SMI,s ...
(Date:10/23/2015)... DUBLIN , Oct. 23, 2015 Research ... of the "Global Voice Recognition Biometrics Market 2015-2019" ... --> --> The global voice recognition ... during 2014-2019. --> ... 2015-2019, has been prepared based on an in-depth market ...
Breaking Biology News(10 mins):
(Date:11/24/2015)... ... November 24, 2015 , ... Copper is an essential ... bound to proteins, copper is also toxic to cells. With a $1.3 million ... (WPI) will conduct a systematic study of copper in the bacteria Pseudomonas aeruginosa ...
(Date:11/24/2015)... Inc., a worldwide provider of clinical research services headquartered in ... has set a new quarterly earnings record in Q3 of 2015.  ... Q3 of 2014 to Q3 of 2015.   ... the establishment of an Asia-Pacific office to ... and Mexico , with the establishment ...
(Date:11/24/2015)... ... November 24, 2015 , ... The Academy of Model ... Group (SIG), MultiGP, also known as Multirotor Grand Prix, to represent the First–Person View ... years. Many AMA members have embraced this type of racing and several new model ...
(Date:11/24/2015)... Ltd. (OTCQB: TIKRF) today announced that its Annual General Meeting of Shareholders ... Israel time, at the law offices of Goldfarb Seligman ... Floor, Tel Aviv, Israel . ... to the Board of Directors; , election of Liat ... an amendment to certain terms of options granted to our Chief Executive ...
Breaking Biology Technology: